

1 **Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction**
2 **of integrase inhibitors antiretroviral based regimens among people living with HIV in**
3 **Tanzania**

4 Makyao Minja¹, Tusaligwe Mbilinyi², Bryceson Mkinga³, Erick G. Philipo⁴, Joyce Owenya⁵, and
5 Manase Kilonzi^{1*}

6 *Affiliations*

7 ¹Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, the Muhimbili
8 University of Health and Allied Sciences, Dar es Salaam, Tanzania.

9 ²Department of Pharmaceutical Microbiology, School of Pharmacy, the Muhimbili University of
10 Health and Allied Sciences, Dar es Salaam, Tanzania.

11 ³Department of Pharmacognosy, School of Pharmacy, the Muhimbili University of Health and
12 Allied Sciences, Dar es Salaam, Tanzania.

13 ⁴Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, the Muhimbili
14 University of Health and Allied Sciences, Dar es Salaam, Tanzania.

15 ⁵Department of Pharmacy, Temeke Regional Referral Hospital, Dar es Salaam, Tanzania.

16 Corresponding author: manasekilonzi@gmail.com, +255 688 045752

17

18

19

20

21 **Abstract**

22 **Objective:** This study aimed to assess the prevalence of CM, treatment practice, and the associated
23 factor's post-introduction of Tenofovir Lamivudine and Dolutegravir (TLD) regimen among
24 PLHIV in Tanzania.

25 **Methods:** This was an analytical cross-sectional study, and the data was collected retrospectively
26 in three public regional referral hospitals (RRHs) in Dar es Salaam, Tanzania. A total of 405 files
27 of the PLHIV admitted in the medical wards on the TLD regimen from January 2019 to December
28 2022 were reviewed. The collected information includes patient demographic characteristics,
29 Cryptococcal status, CD4 level at the time of CM diagnosis, status of using ART, CM treatment
30 approach, and outcome. Data was analyzed using SPSS software version 23.

31 **Results:** Out of 405, the majority 267(65.9%) were female, 224(55.3%) were aged between 36 -
32 55 years, and 293(72.3%) married. ART defaulters were found to be 37(9.1%). The prevalence of
33 CM was found to be 48(11.9%), out of which 42(87.5%) received fluconazole alone. ART
34 defaulter and marital status significantly (p -value < 0.05) were associated with those who tested
35 CM positive.

36 **Conclusion:** The study found the prevalence of CM among PLHIV to be significantly high and
37 the majority were treated with fluconazole alone. ART defaulters and marital status were
38 significantly associated with one being CM positive. Responsible authorities and stakeholders
39 should enforce guideline adherence and PLHIV should be encouraged on medication adherence.

40 **Keywords:** Cryptococcal meningitis, Fluconazole, Triple therapy, Prevalence, Treatment,
41 Tanzania

42

43 **I. Introduction**

44 Cryptococcal Meningitis (CM) is one of the leading causes of laboratory-confirmed meningitis in
45 adults living in countries with a high burden of HIV especially in Sub-Saharan Africa (SSA) [1,2].
46 CM accounts for over 100,000 incident cases of meningitis per year in the SSA [3]. The burden of
47 CM in PLHIV is high and globally is estimated to cause 15%-20% of HIV-related deaths. In low-
48 income countries (LICs) 220,000 cases of CM are estimated per year resulting in 181,000 deaths
49 [4]. In Tanzania, reports have shown that cryptococcosis has 50% fatality at any dose of antifungal
50 given [5]. CM is an opportunistic fungal infection usually affecting immune-compromised hosts
51 like People Living with Human Immune-deficiency Virus (PLHIV), diabetic patients, solid organ
52 transplant recipients, and patients receiving immunosuppressant [6]. The infection is not
53 transferred from person to person, but results from the inhalation of infectious spores mainly found
54 in bird droppings, that multiply in the lungs and can spread to the membranes covering the brain
55 and spinal cord causing meningitis [7]. In HIV-infected patients, the disease is considered as a
56 result of recurrence of latent infection which occurs months to years after the initial exposure event
57 [8,9].

58 In 2019, Tanzania introduced a Dolutegravir (DTG) based regimen of TLD as the preferred first-
59 line antiretroviral therapy (ART) for most adults and adolescents for HIV-1 infections [10]. From
60 the two landmark clinical trials named ADVANCE and NAMSAL performed in SSA, the efficacy
61 of DTG, and non-emergence of resistance support its use as a first-line regimen for ART-naïve
62 adults with HIV-1 [11]. Patients on the DTG-based regimen had high weight and the viral load
63 was suppressed more quickly compared to the Efavirenz-based regimen [12]. TLD is affordable
64 and well tolerated and improves the clinical outcomes of patients) [13,14]. On the other hand, triple
65 therapy of Amphotericin B, flucytosine (5-FC), and fluconazole is recommended for the treatment

66 of CM. The guidelines recommend two weeks of amphotericin B and 5-FC for the induction phase,
67 followed by fluconazole for the merging and maintenance phases of treatment [15]. Studies report
68 that the use of fluconazole alone is inferior and is associated with high morbidity and mortality
69 compared to triple therapy [16]. However, despite advances in HIV, and CM management, the
70 majority of PLHIV-living LICs face hospital acute mortality in the range between 30-50% [17].

71 Other factors associated with the burden of CM among PLHIV are reported to be; Being ART
72 naïve and ART defaulter, being male, living in rural areas, being hospitalized, having low CD4
73 count, and having increasing age with CD4<100 cells, and having body mass index of
74 <18.5kg/m²[18]. Making age, gender, body mass index, and ART adherence major determining
75 factors for cryptococcal infection among PLHIV [19].

76 Similar to other World Health Organization (WHO) member states, Tanzania adopted the use of a
77 integrase inhibitors-based ART regimen as first-line therapy for adults with PLHIV, and through
78 its guidelines, triple therapy was introduced for the management of CM. Despite the efforts made
79 by the WHO and its member states, the majority of deaths among PLHIV are associated with CM
80 [20]. However, there is a scarcity of information with regard to the prevalence of CM and treatment
81 practice's post-introduction of integrase inhibitors-based regimens as first-line therapy for PLHIV
82 in LICs. Therefore, this study aims to determine the prevalence, treatment practice, and associated
83 factors of CM among PLHIV post-introduction of TLD in Dar es Salaam, Tanzania.

84 **II. Materials and Methods**

85 **A. Study design and area**

86 This was a hospital-based cross-sectional study using a retrospective data collection approach.
87 Data were collected from March to June 2023 in public regional referral hospitals (RRHs) in Dar

88 es Salaam, Tanzania i.e., Temeke, Amana, and Mwananyamala referral hospitals. The chosen
89 hospitals have Care and Treatment Centers (CTC) that serve the majority of PLHIV residing in
90 Dar es Salaam city and surrounding areas.

91 **B. Study population**

92 People Living with HIV (PLHIV) admitted to the medical wards on TLD from 2019 to 2022 in
93 the three RRHs (Temeke, Amana, and Mwananyamala).

94 **C. Sample size and sampling technique**

95 A minimum sample size of 153 PLHIV was estimated using the formula for cross-sectional study
96 ($n = p(1-p) z^2/d^2$). Assuming a population of 7.1% from a previous study on the “burden of serious
97 fungal infection” conducted in Tanzania[6], the confidence level of 95% ($z = 1.96$) and precision
98 (d) of 5%,. On data collection, a total of 405 PLHIV on TLD admitted to the medical wards from
99 2019 to 2022 files were retrieved in the three visited RRHs.

100 **D. Data collection**

101 An Excel spreadsheet was used to collect data from patients’ files, laboratory test results, and Care
102 and Treatment Clinic (CTC) cards where sections involving treatment practice and associated
103 factors were included, as information about associated risk factors, treatment practice, and
104 prevalence was obtained. The information was collected with the assistance of the respected
105 facility's responsible healthcare worker. On days of data collection data collectors were given files
106 of the HIV patients admitted in medical wards from 2019 to 2022 from the archives. To observe
107 confidentiality names and other information which could identify the participant were not
108 documented.

109 **E. Data analysis**

110 Data obtained was analyzed by using Statistical Package for Social Science (SPSS) software,
111 version 23. Descriptive statistics was used to summarize socio-demographic and clinical
112 characteristics; the Chi-square test was used to analyze variables associated with the prevalence of
113 CM and treatment outcomes among those who tested CM positive. A p-value below 0.05 was
114 considered statistically significant.

115 **F. Ethical issues**

116 Ethical clearance was obtained from the Muhimbili University of Health and Allied Sciences
117 (MUHAS)- Research Ethics Committee (REC). The protocol stated clear that the study will
118 retrieve information from patients medical records and the clearance was issued MUHAS-REC:
119 Ref. No. DA. 283/298/01L/602). Permission from the three RRHs administrations (Temeke,
120 Amana, and Mwananyamala) was sought before data collection. Patients' files were obtained from
121 medical file archives and special identification number was assigned for each file to protect
122 confidentiality of the participants information. Participants name and another information that
123 could identify the participants were not abducted from the files.

124 **III. Results**

125 **A. Demographic characteristics of study participants**

126 Out of 405 participants, the majority 224 (55.3%) were between 36-55 years followed by
127 98(24.2%), 18-35 years of age. Regarding employment status, the majority 167(41.2%) were self-
128 employed and 293(72.3%) were married. Besides, most 267(65.9%) of the participants were
129 female and 37(9.1%) were ART defaulter(**table1**).

130 *Table 1: Demographic characteristics of study participants (n=405)*

Variables	Median (Range)	n(%)
Age (years)	43 (2-78) years	
Age category (years)		
<18		28(6.9)
18-35		98(24.2)
36-55		224(55.3)
>55		55(13.6)
Sex		
Female		267 (65.9)
Male		138 (34.1)
Occupation		
Employed		150(37.0)
Self-employed		167(41.2)
Unemployed		88(21.7)
Marital status		
Married		293(72.3)
Unmarried		112(27.7)
ART Defaulter		
Yes		37(9.1)
No		368(90.9)

132 **B. Prevalence of CM, CD4 count at diagnosis, treatment approach and**
133 **Outcome of treatment among participants**

134 Out of 405 participants, 48 (11.9%) tested CM positive. Of those who tested positive, 6(12.5%)
135 received triple therapy (fluconazole, 5FC, and amphotericin) while 42(87.5%) received
136 fluconazole alone. Following treatment, 4(8.9%) died, 18(40%) recovered, 17(37.8%) were lost to
137 follow-up, 2(4.4%) were given referral, and 4(8.9%) were on going with treatment (**table 2**).

138 *Table 2: Prevalence of cryptococcal meningitis, CD4 count at diagnosis, treatment approach, and*
139 *Outcome of treatment among participants (n=405)*

Variable	n(%)
Cryptococcal meningitis status (n =405)	
Positive	48(11.9)
Negative	357(88.1)
CD4 count (cells/μL) at diagnosis Cryptococcal meningitis (n =48)	
<200	39(81.3)
\geq 200	9(18.8)
Treatment regimen used (n=48)	
flu, 5FC, and amphotericin B	6(12.5)
fluconazole	42(87.5)
Treatment Outcomes (n=45)	
Died	4(8.9)
Recovered	18(40)
Loss To Follow up	17(37.8)

Referred	2(4.4)
On treatment	4(8.9)

140

141 **C. Factors associated with CM status among study participants**

142 Following Pearson chi-square test, all 37 (100%) ART defaulters tested CM positive compared to
 143 non-defaulters; the difference was statistically significant (p-value < 0.01). While those unmarried
 144 24(21.4%) significantly (p-value < 0.01) tested CM positive compared to those who are in
 145 marriage 24(8.1%). Other factors including age, sex, and occupation were not associated with
 146 being CM-positive among the participants (**table 3**).

147 *Table 3: Showing Pearson chi-square test of the demographic characteristics and Cryptococcal*
 148 *meningitis status among participants (n = 405)*

Variables	Cryptococcal meningitis status		P-value
	Positive	Negative	
Age (years)			
Age category (years)			
<18	0(0.0)	28(100)	0.80
18-35	17(17.3)	81(82.7)	
36-55	25(11.2)	199(88.8)	
>55	6(10.9)	49(89.1)	
Sex			
Female	23(16.7)	115(83.3)	0.31
Male	25(9.4)	242(90.6)	
Occupation			

Employed	8(9.1)	80(90.9)	0.64
Self-employed	20(13.2)	132(86.8)	
Unemployed	20(12.1)	145(87.9)	
Marital status			
Married	24(8.2)	269(91.8)	< 0.01
Unmarried	24(21.4)	88(78.6)	
ART defaulter			
Yes	37(100)	0(0.0)	< 0.01
No	11(3.0)	357(97.0)	

149

150 **D. Factors associated with Cryptococcal meningitis treatment outcomes among**
 151 **study participants**

152 Among those who were given a recommended regimen none died, none neither had loss to follow
 153 up nor referral, 3(60.0%) recovered and 2(40%) were on going with treatments while among those
 154 given fluconazole alone; 4(10%) died, 15(37.5%) recovered, 17(42.5%) were loss to follow up,
 155 2(5%) were referred and 2(5%) are ongoing with treatment and the difference were slightly
 156 significant (p-value = 0.048). Other factors like age, sex, occupation, marital status, ART defaulter
 157 status, and CD4 count at the time of diagnosis were not statistically related to CM treatment
 158 outcome. However, for those who had a CD4 count < 200 cells/ μ L at the time of diagnosis, 4
 159 (11.1%) died, and 12(33.3%) recovered while those who had a CD4 count of \geq 200 cells/ μ L none
 160 died, 6(66.7%) recovered (**table 4**)

161 **Table 4:** Showing Pearson chi-square test of the demographic characteristics and Cryptococcal
 162 meningitis status among participants (n=45)

Variable	Treatment Outcomes n (%)					P-value
	Died	Recovered	Loss To Follow up	Referred	On treatment	
Age category						
<18	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0.31
18-35	0(0.0)	7(46.7)	7(46.7)	1(6.7)	0(0.0)	
36-55	2(8.3)	10(41.7)	8(33.3)	1(4.2)	3(12.5)	
>55	2(33.3)	1(16.7)	2(33.3)	0(0.0)	1(16.7)	
Sex						
Male	3(14.3)	9(42.9)	7(33.3)	1(4.8)	1(4.8)	0.68
Female	1(4.2)	9(37.5)	10(41.7)	1(4.2)	3(12.5)	
Occupation						
Unemployed	0(0.0)	2(28.6)	4(57.1)	1(14.3)	0(0.0)	0.28
Employed	1(5.0)	7(35.0)	10(50.0)	0(0.0)	2(10.0)	
Self employed	3(16.7)	9(50.0)	3(16.7)	1(5.6)	2(11.1)	
Marital status						
Married	3(13.6)	11(50.0)	7(31.8)	0(0.0)	1(4.5)	0.25
Unmarried	1(4.3)	7(30.4)	10(43.5)	2(8.7)	3(13.0)	
ART defaulter						
Yes	3(8.8)	14(41.2)	12(35.3)	1(2.9)	4(11.8)	0.69
No	1(9.1)	4(36.4)	5(45.5)	1(9.1)	0(0.0)	
CD4 count at diagnosis (cells/μL)						
<200	4(11.1)	12(33.3)	15(41.7)	2(5.6)	3(8.3)	

≥200	0(0.0)	6(66.7)	2(22.2)	0(0.00)	1(11.1)	0.37
Treatment regimen						
Flu,5FC, amphotericin	0(0.0)	3(60.0)	0(0.0)	0(0.0)	2(40.0)	0.048
Fluconazole	4(10.0)	15(37.5)	17(42.5)	2(5.0)	2(5.0)	

163

164 **IV. Discussion**

165 The objective of this study was to determine the prevalence, treatment, and factors associated with
 166 CM post-introduction of TLD regimen among PLHIV in Tanzania. Out of 405 reviewed patient
 167 files, the study found that 11.9% had CM, out of which 12.5% received the recommended regimen
 168 (triple therapy = Fluconazole, 5-FC, and amphotericin B) and 87.5% received fluconazole alone.
 169 Following treatment, 40% recovered while 37.8% were lost to follow-up. ART defaulter and
 170 marital status were significantly associated with those who tested CM positive; neither of those
 171 treated with triple therapy died, referred, or lost to follow-up compared to those on fluconazole
 172 alone.

173 The prevalence observed in our study is comparable to what was observed in developing countries
 174 like Cameroon (11.2%), and Ethiopia (11.4%) [21,22]. The reported prevalence is slightly higher
 175 than what was observed in Sierra Leone (7.7%) and Indonesia (7.1%) and higher than what was
 176 reported in London (5%), Nigeria (5.1%) and Haiti (1.1%) [23,24]. Varying prevalence's of CM
 177 were observed in different studies could be due to the type of the study design and data collection
 178 approaches. Also, some studies included all naive and experienced PLHIV patients while others
 179 recruited only those on ART for some time. Our studies assess the CM status of the PLHIV

180 admitted in the hospital for medical reasons which could explain the observed high prevalence.
181 Nevertheless, differences in laboratory protocol, healthcare system, and geographical location of
182 the study settings have been associated with the inconsistency of the reported CM prevalence
183 among PLHIV [25,26]. Since CM is acquired through inhalation of the yeast droplet from the air,
184 weather condition differences may also influence the reported prevalence.

185 The study demonstrated that only 12.5% of those with CM were treated with the recommended
186 regimen which is a combination of Amphotericin B and 5-FC during the induction course and
187 Fluconazole during the completion phase. The uses of Amphotericin B and flucytosine are reported
188 to reduce CM-related mortality by 40% and clinical trials report that the use of fluconazole alone
189 in the management of CM is inferior [16]. Similar to findings from this study PLHIV with CM
190 treated with fluconazole alone, the majority died or were lost to follow-up compared to those given
191 triple therapy. Despite being recommended by WHO and adopted by member countries like
192 Tanzania, the use of triple therapy in the management of CM in most of the developing countries
193 is low [27]. The poor availability of 5-FC and amphotericin B and the associated cost of purchasing
194 the two medications could be a reason for their poor use in developing countries [28]. The use of
195 a drug like amphotericin B requires laboratory tests prior to and during the time of using the drug
196 in order to prevent patients from toxicity [29]. The latter increases the cost of treatment, taking
197 into consideration that the majority of people in developing countries rely on out-of-pocket mode
198 of payment and the level of poverty could be a reason why healthcare providers (HCPs) opt to use
199 fluconazole alone [30].

200 In addition, triple therapy involves a different route of drug administration, as fluconazole and 5-
201 FC are given by infusion, and amphotericin B is given intrathecally. The competency of
202 administering amphotericin B among HCPs and the complexity of monitoring for toxicity could

203 be another reason why most HCPs opt for the use of fluconazole alone [31] Training of the HCPs
204 and people involved in the care of PLHIV on how to use triple therapy should be in place to equip
205 HCPs with knowledge and skills on how to dose and administer the medications [28].
206 Nevertheless, in Tanzania, as in other developing countries patients appear late in the hospital and
207 PLHIV with CM end up admitted and treated as an inpatient through a medical ward. However,
208 medicines and consumables for PLHIV which are purchased and sent to the facilities through a
209 vertical program are available in the CTC. Therefore, proper communication should be initiated to
210 ensure PLHIV admitted in the wards receive medications from CTC. The latter will foster the use
211 of triple therapy as fluconazole, 5-FC, and amphotericin B are grouped as drugs for opportunistic
212 infections (OIs) and are procured through vertical programs [29,32].

213 The study also observed that ART defaulters were significantly associated with those who tested
214 CM positive. The findings are consistent with what has been reported repeatedly that stopping the
215 use of ART leads to increased viral load, suppressing CD4 cells, and exposing patients to OIs like
216 CM. HIV infection is the common risk of CM, as the risk is estimated to be 95% in PLHIV living
217 in middle-low-income countries and 80% in high-income countries. Despite TLD being effective
218 and user-friendly, current studies still report inadequate adherence to ART among PLHIV [33,34].
219 Although WHO recommends screening for CM to PLHIV with CD4 levels < 100/ul and naive,
220 studies report the significant prevalence of CM among ART-experienced patients. To fight against
221 the deadly disease, screening for CM among PLHIV should be done regularly despite the CD4
222 level and years of being on ART [18]. Furthermore, the use of fluconazole as prophylaxis should
223 be scaled up to all PLHIV, particularly in developing countries where the majority have immune
224 problems and access to medical care is a challenge [35]. The latter is possible by taking the

225 example of Isoniazid prophylaxis therapy (IPT) for the prevention of tuberculosis among PLHIV
226 [19].

227 The study found that the prevalence of CM was higher among unmarried people compared to
228 married people. Several studies report the importance of PLHIV having a close relative/friend or
229 spouse be aware of his/her status [36,37]). Advantages of disclosing HIV status include reducing
230 the level of stigma, having someone to remind a patient to take medication, and clinic schedules
231 and it improves the quality of living [38]. Therefore, more efforts should be implemented to ensure
232 that the majority of PLHIVs disclose the status at least to one of the close spouses/relative or friend.
233 Moreover, our study found no significant difference in CM prevalence between males and females.
234 The findings are not similar to what was reported in other studies in which the prevalence of CM
235 was high in males compared to females [20]. The difference observed could be due to the study
236 setting; our study was conducted in the city of Dar es Salaam, in which both men and women are
237 considered breadwinners of the family [39]. Therefore, being outdoors both men and women are
238 equally exposed to contaminated environments.

239 **V. Conclusion**

240 The study found the prevalence of CM among PLHIV to be significantly high. Unlike the guideline
241 recommendation, the majority of PLHIV with CM were treated with fluconazole alone instead of
242 triple therapy. ART defaulters and marital status were significantly associated with one being CM
243 positive. Responsible authorities and stakeholders should enforce guideline adherence and a
244 mechanism should be instituted to ensure PLHIV adheres to medication. Taking an example of
245 tuberculosis treatment, in which a victim must visit the clinic with a relative, strategies should be
246 proposed to ensure PLHIV discloses their status to at least a spouse/relative or a close friend.

247 **VI. List of abbreviation**

248 **5-FC:** 5-fluorocytosine(Flucytosine), **ART:** Antiretroviral Therapy, **CTC:** Care and Treatment
249 Centre, **CD4:** Clusters of Differentiation 4, **CM:** Cryptococcal meningitis, **PLHIV:** People Living
250 With Human Immunodeficiency Virus, **HIV:** Human Immunodeficiency Virus, **HCPs:** Health
251 Care Providers, **IPT:** Isoniazid Prophylaxis Therapy, **LIC:** Lower Income Countries, **MUHAS:**
252 Muhimbili University of Health and Allied Sciences, **RRH:** Regional Referral Hospitals, **SPSS:**
253 Statistical Package for Social Science, **TLD:** Tenofovir Lamivudine Dolutegravir

254 **VII. Acknowledgements**

255 The authors sincerely thank the Muhimbili University of Health and Allied Sciences – Research
256 and Ethics Committee (MUHAS-REC) for providing ethical clearance and administration of the
257 visited hospitals for providing permission to conduct data collection. We also thank each appointed
258 hospital HCP who helped data collectors to retrieve files and clarified some of the unexplained
259 information.

260 **VIII. References**

- 261 1. Kisenge PR, Hawkins AT, Maro VP, Mchele JPD, Swai NS, Mueller A, et al. Low CD4
262 count plus coma predicts cryptococcal meningitis in Tanzania. *BMC Infect Dis.* 2007;7: 1–
263 5. doi:10.1186/1471-2334-7-39.
- 264 2. Britz E, Perovic O, Von Mollendorf C, Von Gottberg A, Iyaloo S, Quan V, et al. The
265 epidemiology of meningitis among adults in a south African province with a high HIV
266 prevalence. 2009-2012. *PLoS One.* 2016;11: doi:10.1371/journal.pone.0163036.
- 267 3. Muzazu SGY, Assefa DG, Phiri C, Getinet T, Solomon S, Yismaw G, et al. Prevalence of

- 268 cryptococcal meningitis among people living with human immuno-deficiency virus and
269 predictors of mortality in adults on induction therapy in Africa: A systematic review and
270 meta-analysis. *Front Med.* 2022;9: 1–13. doi:10.3389/fmed.2022.989265
- 271 4. Radha Rajasingham, Rachel M Smith, Benjamin J Park, Joseph N Jarvis, Nelesh P
272 Govender, Tom M Chiller et al. Global burden of disease of HIV-associated cryptococcal
273 meningitis: an updated analysis. *Lancet Infect Dis.* 2017;17(8):873-881. doi:
274 10.1016/S1473-3099(17)30243-8.
- 275 5. Faini D, Maokola W, Furrer H, Hatz C, Battegay M, Tanner M, et al. Burden of serious
276 fungal infections in Tanzania. *Mycoses.* 2015;58: 70–79. doi:10.1111/myc.12390.
- 277 6. Teekaput C, Yasri S, Chaiwarith R. Cryptococcal Meningitis: Differences between Patients
278 with and without HIV-Infection. *Pathogens.* 2023;12. doi:10.3390/pathogens12030427.
- 279 7. Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission
280 of *Cryptococcus neoformans* by organ transplantation. *Clin Infect Dis.* 2011;52: 94–98.
281 doi:10.1093/cid/ciq216.
- 282 8. Joel Schop. Protective immunity against *cryptococcus neoformans* infection. *McGill J Med.*
283 2007;10: 35–43. doi:10.26443/mjm.v10i1.467.
- 284 9. Ngan NTT, Flower B, Day JN. Treatment of Cryptococcal Meningitis: How Have We Got
285 Here and Where are We Going? *Drugs.* 2022;82: 1237–1249. doi:10.1007/s40265-022-
286 01757-5
- 287 10. NASP. National Guidelines for the Management of HIV and AIDS. Development. 2019;7:
288 2,274,923,575.

- 289 11. Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al.
290 Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1
291 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open
292 label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV*. 2020;7: e677–e687.
293 doi:10.1016/S2352-3018(20)30238-1
- 294 12. de Faria Ferreira M, Brito-Santos F, Henrique Nascimento Theodoro P, de Abreu Almeida
295 M, Lazera M dos S, Trilles L. Mixed infection by *Cryptococcus neoformans* and
296 *Cryptococcus gattii* and coinfection with paracoccidioidomycosis in PLHIV. *Med Mycol*
297 *Case Rep*. 2022;35: 48–50. doi:10.1016/j.mmcr.2022.01.006
- 298 13. Ouedraogo D, Cissoko Y, Soumare M, Alle Akakpo AE, Loua O-O, Konate I, et al.
299 Neuromeningeal Cryptococcosis and Tuberculosis Coinfection in Bamako: A One-Year
300 Case Series. *Open Forum Infect Dis*. 2023;10: 1–4. doi:10.1093/ofid/ofad438
- 301 14. Perfect JR, Dismukes WE, Dromer F, Goldman DL, John R, Hamill RJ, et al. Guideline for
302 cryptococcus. *Clin Infect Dis*. 2018;50: 291–322. doi:10.1086/649858.Clinical
- 303 15. Miot J, Leong T, Takuva S, Parrish A, Dawood H. Cost-effectiveness analysis of flucytosine
304 as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in
305 South Africa. *BMC Health Serv Res*. 2021;21: 1–11. doi:10.1186/s12913-021-06268-9
- 306 16. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis:
307 Time to urgently address the worldwide accessibility of a 50-year-old antifungal. *J*
308 *Antimicrob Chemother*. 2013;68: 2435–2444. doi:10.1093/jac/dkt221
- 309 17. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose

- 310 response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in
311 southwestern Uganda. *Clin Infect Dis*. 2008;47: 1556–1561. doi:10.1086/593194
- 312 18. Abassi M, Boulware DR, Rhein J. Cryptococcal Meningitis: Diagnosis and Management
313 Update. *Curr Trop Med Reports*. 2015;2: 90–99. doi:10.1007/s40475-015-0046-y
- 314 19. Hailu K, Niguse S, Hagos K, Abdulkader M. Cryptococcal antigenemia and associated risk
315 factors among ART-naïve and ART-experienced HIV-infected peoples at selected health
316 institutions of Mekelle, Northern Ethiopia. *Microbiologyopen*. 2019;8: 1–8.
317 doi:10.1002/mbo3.746
- 318 20. Negash M, Wondmagegn T, Tajebe F. Opportunistic Cryptococcal Antigenemia in the
319 HAART Era at HIV Epidemic Settings of Northwest Ethiopia. *Can J Infect Dis Med*
320 *Microbiol*. 2020;2020. doi:10.1155/2020/5017120
- 321 21. Jemal M, Deress T, Belachew T, Adem Y. Prevalence of Cryptococcal Antigenemia and
322 Associated Factors among HIV / AIDS Patients at Felege-Hiwot Referral Hospital , Bahir
323 Dar , Northwest Ethiopia. 2021;2021.
- 324 22. Luma HN, Temfack E, Halle MP, Nguenkam Tchaleu BC, Mapoure YN, Koulla-Shiro S.
325 Cryptococcal meningoencephalitis in human immunodeficiency virus/acquired
326 immunodeficiency syndrome in Douala, Cameroon: A cross sectional study. *N Am J Med*
327 *Sci*. 2013;5: 486–491. doi:10.4103/1947-2714.117318
- 328 23. Lakoh S, Rickman H, Sesay M, Kenneh S, Burke R, Baldeh M, et al. Prevalence and
329 mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital
330 in Sierra Leone: A prospective study. *BMC Infect Dis*. 2020;20: 1–7. doi:10.1186/s12879-

331 020-4862-x

332 24. Geda N, Beyene T, Dabsu R, Mengist HM. Prevalence of Cryptococcal Antigenemia and
333 associated factors among HIV/AIDS patients on second-line antiretroviral therapy at two
334 hospitals in Western Oromia, Ethiopia. *PLoS One*. 2019;14: 1–13.
335 doi:10.1371/journal.pone.0225691

336 25. Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal
337 meningitis: A neglected NTD? *PLoS Negl Trop Dis*. 2017;11: 1–7.
338 doi:10.1371/journal.pntd.0005575

339 26. Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B. Cryptococcal
340 antigen screening and early antifungal treatment to prevent cryptococcal meningitis: A
341 review of the literature. *J Acquir Immune Defic Syndr*. 2015;68: S331–S339.
342 doi:10.1097/QAI.0000000000000484

343 27. WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease.
344 2018.

345 28. Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response
346 to new evidence and guidelines for the management of cryptococcal meningitis in low-
347 income and middle-income countries. *Lancet Infect Dis*. 2019;19: e143–e147.
348 doi:10.1016/S1473-3099(18)30493-6

349 29. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al.
350 Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. *N Engl J*
351 *Med*. 2018;378: 1004–1017. doi:10.1056/nejmoa1710922

- 352 30. Kitole FA, Lihawa RM, Mkuna E. Equity in the public social healthcare protection in
353 Tanzania: does it matter on household healthcare financing? *Int J Equity Health*. 2023;22:
354 1–14. doi:10.1186/s12939-023-01855-0
- 355 31. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of
356 Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal
357 Infections. *Infect Dis Ther*. 2021;10: 115–147. doi:10.1007/s40121-020-00382-7
- 358 32. isangula KG. Prevention of Mother to Child Transmission of HIV Program in Tanzania:
359 Service Delivery and Uptake Constraints. *SSRN Electron J*. 2012.
360 doi:10.2139/ssrn.1976890
- 361 33. Kilapilo MS, Sangeda RZ, Bwire GM, Sambayi GL, Mosha IH, Killewo J. Adherence to
362 Antiretroviral Therapy and Associated Factors Among People Living With HIV Following
363 the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. *J Int Assoc
364 Provid AIDS Care*. 2022;21: 1–8. doi:10.1177/23259582221084543
- 365 34. Alufandika M, Lawrence DS, Boyer-Chammard T, Kanyama C, Ndhlovu CE, Mosepele M,
366 et al. A pragmatic approach to managing antiretroviral therapy-experienced patients
367 diagnosed with HIV-associated cryptococcal meningitis: Impact of antiretroviral therapy
368 adherence and duration. *Aids*. 2020;34: 1425–1428. doi:10.1097/QAD.0000000000002556
- 369 35. Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, et al. Short-course
370 amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated
371 cryptococcal meningitis in rural Tanzania. *Mycoses*. 2019;62: 1127–1132.
372 doi:10.1111/myc.12995

- 373 36. Xu JF, Ming ZQ, Zhang YQ, Wang PC, Jing J, Cheng F. Family support, discrimination,
374 and quality of life among ART-treated HIV-infected patients: A two-year study in China.
375 *Infect Dis Poverty*. 2017;6: 1–10. doi:10.1186/s40249-017-0364-5
- 376 37. Banagi Yathiraj A, Unnikrishnan B, Ramapuram JT, Kumar N, Mithra P, Kulkarni V, et al.
377 Factors Influencing Adherence to Antiretroviral Therapy among People Living with HIV in
378 Coastal South India. *J Int Assoc Provid AIDS Care*. 2016;15: 529–533.
379 doi:10.1177/2325957416661424
- 380 38. Hallberg D, Kimario TD, Mtuya C, Msuya M, Björling G. Factors affecting HIV disclosure
381 among partners in Morongo, Tanzania. *Int J Africa Nurs Sci*. 2019;10: 49–54.
382 doi:10.1016/j.ijans.2019.01.006
- 383 39. Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N, et al. Brief
384 Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia among HIV-
385 Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study. *J*
386 *Acquir Immune Defic Syndr*. 2016;73: 117–121. doi:10.1097/QAI.0000000000001048
- 387